Is CMV Causing Your Ulcerative Colitis Flare-Up? A New Way to Tell
"Discover how a simple clinical model can help detect cytomegalovirus (CMV) infection during ulcerative colitis (UC) exacerbations, leading to faster treatment and better outcomes."
Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon, characterized by periods of remission and flare-ups. Managing these flare-ups can be challenging, as various factors can trigger them, including infections. One such infection is cytomegalovirus (CMV), a common virus that can reactivate during periods of immune suppression.
While CMV is frequently detected in the colonic biopsies of UC patients, especially those with steroid-refractory UC, its exact role remains controversial. Is it merely an innocent bystander, or does it actively contribute to the worsening of UC symptoms? Distinguishing between these possibilities is critical for determining the appropriate course of treatment.
A recent study published in 'Digestion' provides a promising clinical model to detect CMV infection in UC patients experiencing exacerbations. This model relies on readily available clinical parameters, offering a way to quickly assess the likelihood of CMV involvement and guide timely interventions. Here's a breakdown of the study and its potential implications for managing UC.
CMV in UC: Prevalence and Impact
A hospital-based study in Nepal estimated CMV colitis prevalence at 10.28% among patients with ulcerative colitis (UC), including 28.57% in acute severe UC (ASUC) and 7.69% during a UC flare-up. A 2023 report says CMV reactivation may contribute to acute exacerbations in severe UC and that patients whose symptoms are exacerbated by CMV have greater morbidity and mortality. The role of CMV in UC flare-ups remains unclear, and CMV can produce similar symptoms in different clinical contexts. The ClinicalTrials.gov record notes that accurate, timely detection and appropriate antiviral therapy may reduce complications associated with an acute UC flare.
Diagnosis and Treatment Remain Unsettled
In UC, the effect of CMV infection and the role of antiviral treatment remain unclear. A 2020 review says the role of CMV in worsening UC inflammation and its response to treatment are debatable, while optimal diagnostic tests during relapse and the timing of antiviral treatment initiation remain uncertain. A 2024 report identifies older age over 30, pancolitis, histologic inflammation, and immunosuppressive therapy as risk factors for CMV infection in inflammatory bowel disease. It also describes ongoing efforts to resolve questions about diagnosis, antiviral treatment, and CMV’s impact on UC.
The CMV-UC Connection: Unpacking the Research
The study, led by Avi Levin, Shaul Yaari, and colleagues, retrospectively analyzed data from patients hospitalized for UC exacerbations. The researchers aimed to identify clinical and pathological parameters associated with CMV infection in the colon. They compared various methods for detecting CMV, including histopathology, immunohistochemistry (IHC), and CMV-PCR, to determine the most effective approach.
- CMV-PCR was the most sensitive method for detecting CMV in colonic tissue, outperforming histopathology and IHC.
- CMV-positive patients had a significantly higher frequency of recent steroid treatment and fever.
- They also had higher mean partial Mayo scores (indicating more severe disease activity) and lower mean albumin levels.
- Multivariate analysis identified recent steroid treatment and fever as independent predictors of colonic CMV infection.
New Findings Link Tissue CMV to Disease Activity
A retrospective cohort study reports that, in moderate-to-severe UC, tissue CMV DNA positivity at 250 copies or more was associated with increased clinical and endoscopic disease activity, even without classical histopathological evidence of CMV infection. A 2025 study likewise found that CMV prevalence rose with higher clinical disease activity (p < 0.001) and was associated with more severe endoscopic inflammation (p = 0.002) and histologic inflammation (p = 0.004). These findings describe associations and do not by themselves establish that CMV caused the more active disease. A 2026 study description notes that CMV’s effects on cytokine regulation in UC remain unclear and says it investigated cytokine profiles in 190 CMV-positive and CMV-negative UC patients.
Blood Tests Alone Cannot Rule Out CMV Colitis
The GIandHepatology clinical answer recommends considering CMV colitis particularly in severe or steroid-refractory UC, including when symptoms do not improve despite appropriate therapy. It says diagnosis relies on colonic biopsies, preferably from inflamed or ulcerated mucosa, using histology and immunohistochemistry. Blood testing alone is insufficient to exclude tissue-invasive disease. This guidance underscores the need to assess colonic tissue when CMV is suspected in these cases.
Available Comparisons Do Not Address CMV
The listed comparative sources concern ulcerative colitis but do not compare CMV-positive and CMV-negative disease or evaluate CMV as a cause of flare-ups. One record compares rectal cell proliferation findings with 20 controls without colonic disease and 16 patients with multiple nonfamilial colonic adenomas. Another reports a trend in incidence from severe to moderate to mild disease (P < 0.05) and discusses extra-intestinal manifestations in relation to active UC. A third describes a methodology involving 485 patients with UC seen since 1980; the supplied information does not provide comparative results relevant to CMV.
What This Means for You: A Practical Takeaway
This study offers a valuable tool for clinicians managing UC patients experiencing flare-ups. By incorporating this clinical model into their assessment, doctors can more quickly identify patients at high risk for CMV infection. This, in turn, can lead to earlier initiation of appropriate diagnostic tests, such as CMV-PCR, and timely implementation of antiviral therapy when needed. While further research is always warranted, this clinical model represents a significant step forward in optimizing the management of UC and improving patient outcomes.
Clarifying CMV’s Impact and Testing in UC
A September 2026 report says CMV is frequently detected in UC, particularly in severe or refractory disease, but its impact on disease activity, long-term course, and clinical outcomes remains controversial. An ECCO-JCC abstract describes consecutive patients hospitalized with moderate-to-severe UC from January 2020 through June 2023 who were tested for CMV colitis at hospitalization alongside other infections. In that abstract, CMV colitis was diagnosed by immunohistochemistry on colonic mucosal samples or on resected colon specimens. The supplied material does not report the study’s results, leaving the clinical significance of CMV and its diagnosis in UC as open questions.